Skip to content

Pheno- & Genotyping POF (WHO III)

Phenotyping and Genotyping of Women Presenting With Ovarian Dysfunction Associated With a Hypergonadotropic Hypo-estrogenic Hormonal Status (WHO III) and Their First and Second Degree Relatives

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01411644
Enrollment
650
Registered
2011-08-08
Start date
2005-01-31
Completion date
2020-06-30
Last updated
2018-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Menopause, Hypergonadotropic Amenorrhea, Incipient Ovarian Failure, Poor Response After Ovarian Hyperstimulation, Premature Ovarian Failure (POF)

Keywords

POF, IOF, Poor response, early menopause, Primary amenorrhea

Brief summary

This study focuses on the phenotyping and genotyping of women with hypergonadotropic ovarian dysfunction (WHO III status).

Detailed description

First goal of the study is to phenotype patiens with hypergonadotropic ovarian dysfunction (WHO III) adequately. This group includes women with premature ovarian failure (POF), incipient ovarian failure (IOF), poor response after ovarian hyperstimulation, early menopause and hypergonadotropic primary amenorrhea. The standardized phenotyping consists of a questionnaire focusing on reproductive, medical, and family history; ultrasonography to assess ovarian reserve and/or antral follicle count and obtaining an extra blood sampling during routine endocrine screening for genotyping. Phenotyping of patients presenting with ovarian dysfunction is of crucial importance when genotyping will be performed. The goal of this genotyping will be the identification of genetic factors associated with the (premature) depletion of the stock of ovarian follicles. It will be performed for isolated WHO III patients in an association (case-control) study for known candidate genes. In familial WHO III cases, genome wide linkage analysis will be performed.

Interventions

None listed

Sponsors

Erasmus Medical Center
CollaboratorOTHER
Medical Center Alkmaar
CollaboratorOTHER
University Medical Center Groningen
CollaboratorOTHER
Leiden University Medical Center
CollaboratorOTHER
Medisch Spectrum Twente
CollaboratorOTHER
Isala
CollaboratorOTHER
Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.
CollaboratorOTHER
Amphia Hospital
CollaboratorOTHER
Deventer Ziekenhuis
CollaboratorOTHER
Catharina Ziekenhuis Eindhoven
CollaboratorOTHER
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CollaboratorOTHER
Academisch Ziekenhuis Maastricht
CollaboratorOTHER
Amsterdam UMC, location VUmc
CollaboratorOTHER
UMC Utrecht
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* POF; defined as secondary amenorrhea before 40 years of age and basal FSH \> 40 IU/L * Incipient ovarian failure; defined as normo-ovulatory cycles, raised basal FSH \> 12 IU/L * Poor response patients; defined as less than 4 oocytes retrieved or cancellation in case of absent follicle growth after ovarian hyperstimulation with 300 IU gonadotropins or cancellation in case of absent follicle growth * Women with early menopause (between 40-45 years) * Hypergonadotropic primary amenorrhea

Exclusion criteria

* Primary amenorrhea with early development disorders causing absence of ovaries and Swyer syndrome (XY)

Countries

Netherlands

Contacts

Primary ContactF. Janse, MD
f.janse@umcutrecht.nl+31 88 75 55555
Backup ContactA. J. Goverde, MD, PhD
a.j.goverde@umcutrecht.nl+31 88 75 55555

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026